Clinical trials comparing moderate to intensive statin therapy ARBITER, carotid ultrasound; REVERSAL, coronary IVUS; PROVE-IT, morbidity and mortality.
| Trial Name | LDL-C/HDL-C at Baseline | n | Years | Control (C) | Treatment (T) | %Δ LDL-C C/T | Δ Imaging Endpoint C/T (p Value) | Events C/T |
|---|---|---|---|---|---|---|---|---|
| ARBITER | ∼152/49 | 138 | 1 | Pravastatin (40 mg) | Atorvastatin (80 mg) | –27/–49 | cIMT + 0.025/–0.034 (mean mm/year) (p < 0.03) | 1/0 |
| REVERSAL | 150/42 | 502 | 1.5 | Pravastatin (40 mg) | Atorvastatin (80 mg) | –25/–46 | Δ TAV + 2.7%/–0.4% (p = 0.02) | 9/6 |
| PROVE-IT | ∼110/∼39 | 4162 | ≤3 | Pravastatin (40 mg) | Atorvastatin (80 mg) | –21/–49 at 30 days | N.A. | 10%/8.3% death/MI |
TAV, total atheroma volume; N.A., not available